Lori Firmani, CFO of Galecto, Inc. ($GLTO), made two open market sales of company shares over the past year, totaling $3,389. Her most recent sale occurred on January 2, 2026. These GLTO insider sales rank 11,450th out of 11,678 individuals in the database, well below the average of $8.6 million per insider across 6.4 transactions. Firmani recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Chief Financial Officer | M | Restricted Stock Units | 374 | $0.00 | 726.0000 | 1,327,212 | 34.00% | 0.03% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Chief Financial Officer | S | Common Stock | 135 | $21.41 | 931.0000 | 1,327,212 | 12.66% | 0.01% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Chief Financial Officer | M | Common Stock | 374 | $0.00 | 1,066.0000 | 1,327,212 | 54.05% | 0.03% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | M | Common Stock | 374 | $0.00 | 839.0000 | 1,322,359 | 80.43% | 0.03% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | S | Common Stock | 147 | $3.39 | 692.0000 | 1,322,359 | 17.52% | 0.01% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | M | Restricted Stock Units | 374 | $0.00 | 1,100.0000 | 1,322,359 | 25.37% | 0.03% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | A | Stock Option (right to buy) | 5000 | $0.00 | 5,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | M | Restricted Stock Units | 726 | $0.00 | 1,474.0000 | 0 | 33.00% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | S | Common Stock | 261 | $5.63 | 465.0000 | 0 | 35.95% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | M | Common Stock | 726 | $0.00 | 726.0000 | 0 | 9999.99% | 0.00% |
| Oct. 9, 2024 | Damora Therapeutics, Inc. | $DMRA | Firmani Lori | Interim CFO | A | Stock Option (right to buy) | 13000 | $0.00 | 13,000.0000 | 0 | 9999.99% | 0.00% |